The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).
Age 18-80 years old
Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria
Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion
Documented refractoriness to lenalidomide.
Have lenalidomide exposure within 12 months prior to randomization